Looking at top Wall Street opinions, Whiting Petroleum Corporation (NYSE: WLL) has recently made its way into the research list of KeyBanc Capital Markets – signaling that their analyst’s rating adjustment is noteworthy. This stock was Overweight in the eyes of KeyBanc Capital Markets, as reported on Tuesday, February 12th, 2019. Another heavy-hitting research note was published by Stephens on Thursday December 6th, 2018, with this firm Initiated WLL to an updated rating of Overweight. In the past six months and three months of trading, shares of Whiting Petroleum Corporation (WLL) have moved by -40.32% and -23.17%, respectively.
Brokerage Updates Related to Whiting Petroleum Corporation (WLL) Stock
This publicly-traded organization generated losses of -3.75% over the last 5 sessions. Right now, this stock is the subject of 33 analysts’ evaluations, who – on average – have given this company’s shares a Buy rating. Not a Single analyst have given underperform rating or sell rating, and 9 have given a rating of Buy or better. Based on the 33 stock market experts following this company, the average 12-month price target is $42.17. Moreover, individual price targets range between $20.00-$60.00. With its recent move to $37.00, we can see that these firms project this stock will gain by 18.87% in one year.
Updates from Whiting Petroleum Corporation (WLL) SEC Form 4
This particular company’s shares have garnered a lot of attention in recent days, as insiders are unloading their holdings while having generated a 0.60% rise since the beginning of the calendar year. A Director at Whiting Petroleum Corporation (WLL) sold off some of its shares in a transaction that was finalized on Nov 07. Similarly, STEVENS MICHAEL J sold 12,476 shares of the organization’s stock at $55.04 apiece and racked up $686,688 in earnings from the sale. Now, STEVENS MICHAEL J holds 84,095 shares of the company following the exchange. A Senior Vice President of the organization named Ross Rick A Mr., was engaged in a transaction that occurred on Oct 01 that managed to be worth $114,361 from the sale of 2,079 common shares at a price of $55.01 per individual share.
Whiting Petroleum Corporation (NYSE:WLL) Results in the Pipeline
The next scheduled release of financial results for Whiting Petroleum Corporation will be for the Sep-18 quarter. As it stands right now, market analysts are anticipating the per-share earnings for the three-month period will be $0.58. In the same vein, they expect sales for the quarter to amount to $521.27 million.
Now let’s turn to earnings surprise history: in the most recent quarter, the company reported about $566.70 million in revenue alongside EPS at $0.92. On average, the analyst projection was calling for $526.40 million with $0.63 per share in earnings, respectively. In the preceding quarter, this company’s revenue reached $515.08 million, with earnings per share ending up at $0.92.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) experienced a drop of -0.40% from the closing price in the previous trading day. That drove the price to $17.28 per share, as observed on February 13th, 2019, at a time when the total trading volume reached 2,194,650 shares of stock – compared to the typical average of 1.75M shares per day (as recorded over the past three months). The consensus estimate for these shares has been shifted to $23.30.
Pricing Indications for Arrowhead Pharmaceuticals, Inc. (ARWR)
This organization has had a price-to-earnings ratio of in the last year. In the most recent trading session, the daily high was $17.77, bringing the per-share value -0.40% high its 52-week high and about -22.82% more expensive than its 52-week low. Meanwhile, it gained 13.87 from its observable 50-day simple moving average. Right at this moment, the per-share value is 24.59% higher than the mean per-share price over the last 200 days in the market.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) In-Depth Brokerage Insights
We can see that a number of brokerage firms are putting their focus onto this stock. Out of this group, 0 have a sell rating, 2 have a Buy rating, 4 have an outperform rating, while 0 provided a Hold rating for these shares – thanks to data from Thomson Reuters I/B/E/S. Additionally, 0 have recommended that these shares are an Underperforming investment. The current consensus recommendation is at 1.70 , based on information from Thomson Reuters.
ARWR Stock Value Potential
In trading activity as of late, this stock’s value was 13.92 up from its 200 day moving average, while also 25.07% up when compared against its 50-day simple moving average. Over the course of the past year of trading, the share price stuck in the range of $19.00-$31.00. The market value for the entire organization reached 1.57B. After the trading day started off at the price of $17.28, these shares nearly bottomed out at its low price of $17.12 and nearly peaked at $17.77 as its full-day high price. In the last trading session, the price ended the day at $17.35. The institutional holdings related to this organization account for 4.60%, and the Beta factor is now 2.13. This company’s RSI (Relative Strength Index) managed to hit 67.67.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Analyst Points of Focus
Arrowhead Pharmaceuticals, Inc. (ARWR) has found itself inside of B. Riley FBR’s research list, so their analyst rating adjustment is worth taking note of. This stock was upgraded to Buy, compared to its previous rating of Neutral by B. Riley FBR, as garnered from a news report on Friday September 7th, 2018. An additional helpful research note was sent out by Chardan Capital Markets’s on Thursday September 6th, 2018. The brokerage decided to reiterated ARWR to Buy.